Skip To Main Content
Christina E. Barkauskas on Muck Rack

Christina E. Barkauskas

As seen in: Environmental Health Perspectives, Memory Studies, PLOS Medicine, The Lancet, Texas Medical Center
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christina E.

Contact Christina E., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials

|
By Kirk U. Knowlton, Lianne Siegel, Christina E. Barkauskas, Duke Medicine
| PLOS Medicine Verified
Discussion This study is an individual patient data meta-analysis of six randomized placebo-controlled trials of passive immunotherapies involving 3,079 patients hospitalized with documented SARS-CoV-2 infection and COVID-19 symptoms for ≤12 days. Five out of six of the trials were conducted on the ACTIV-3/TICO platform, with identical definitions of the primary endpoint and harmonized data collection.
Open in Who Shared Issue with article?

Intravenous Aviptadil and Remdesivir for Treatment of COVID-19-Associated Hypoxaemic Respiratory Failure in the USA (Tesico): A Randomised, Placebo-Controlled Trial

|
By Samuel Brown, Christina E. Barkauskas, Birgit Grund, Shweta Sharma Verified
| Texas Medical Center
BACKGROUND: There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. METHODS: TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA.
Open in Who Shared Issue with article?

Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

|
By Samuel Brown, Christina E. Barkauskas, Andrew Phillips
| The Lancet Verified
Summary Background There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. Methods TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA.
Open in Who Shared Issue with article?
See all 6 licensed articles (7 Total)